EMA — authorised 26 April 2019
- Marketing authorisation holder: SANOFI-AVENTIS GROUPE
- Status: approved
🇪🇺 Inpefa in European Union
EMA authorised Inpefa on 26 April 2019
Marketing authorisations
EMA — authorised 26 April 2019
- Application: EMEA/H/C/004889
- Marketing authorisation holder: Guidehouse Germany GmbH
- Local brand name: Zynquista
- Indication: Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
- Status: withdrawn
Inpefa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in European Union
Frequently asked questions
Is Inpefa approved in European Union?
Yes. EMA authorised it on 26 April 2019; EMA authorised it on 26 April 2019.
Who is the marketing authorisation holder for Inpefa in European Union?
SANOFI-AVENTIS GROUPE holds the EU marketing authorisation.